Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis

A prospective, randomised and placebo-controlled study of 66 children, aged 6–36 months, who were hospitalised due to acute diarrhoea caused by rotavirus.

The children were randomised into three groups: placebo (n=25) or Lactobacillus reuteri ATCC 55730 in a daily dose of 10^7 (n=20) or 10^10 CFU (n=21) for up to five days. All three groups received standard rehydration therapy.

From the second day of treatment, 30% of the children given the lower Lactobacillus reuteri dose were free from watery diarrhoea, compared to 52% of the children given the higher dose. The difference was significant for the high-dose Lactobacillus reuteri group compared to the control group, in which 20% of the children no longer had watery diarrhoea. The high-dose group also had a significantly shorter period of watery diarrhoea: 1.5 days on average compared to 2.5 days in the control group. For the low Lactobacillus reuteri dose group, the mean duration of watery diarrhoea was 1.9 days.

Fig. 1 Percentage of patients with persisting watery diarrhea in the groups receiving placebo (n=25) and small (n=20) and large (n=21) dosages of Lactobacillus reuteri.

Conclusion: The administration of Lactobacillus reuteri in the dose of 10^10 CFU per day significantly shortened the duration of watery diarrhoea in children hospitalised for treatment of acute diarrhoea. The low dose of 10^7 CFU almost reached significant effect on duration of watery diarrhoea.

Reference

Shornikova AV, Casas IA, Mykkänen N, Salo E, Vesikari T. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J 1997;16:1103-1107.